{"product_id":"biomedrealty-pestle-analysis","title":"BioMed Realty PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our PESTLE Analysis of BioMed Realty—uncover how political shifts, economic cycles, and tech innovations will shape its real estate strategy and returns; buy the full report for detailed risks, opportunities, and ready-to-use insights to inform investments or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment R\u0026amp;D funding levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cppublic investment via nih and ukri underpins biomed realty tenant pipeline awarded in fy2024 committed directly supporting startups that lease specialized lab space.\u003e\n\u003cpas of late proposed u.s. federal r shifts a fy2026 discretionary plan reducing some non-defense research growth to constrain seed-stage firm formation and leasing demand.\u003e\n\u003cpsustained government commitment shown by a cagr in us federal biomedical funding since is critical to maintaining steady demand for biomed high-spec research environments.\u003e\n\u003c\/psustained\u003e\u003c\/pas\u003e\u003c\/ppublic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability in innovation hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMed Realty’s holdings concentrated in Boston, San Francisco Bay Area and Cambridge UK—regions generating over 40% of US and 25% of UK life‑science VC deal value in 2024—make geopolitical stability vital to tenant demand and rental growth.\u003c\/p\u003e\n\u003cp\u003eChanges to visa rules or trade tensions that reduced cross‑border researcher flows by even 10% would risk lower lab occupancy and delay projects, impacting projected NOI and multi‑year development schedules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing legislation and policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical efforts like the US Inflation Reduction Act, which enabled Medicare drug price negotiations projected to lower drug spending by an estimated $100 billion over 10 years (CBO, 2024), pressure Big Pharma margins and can prompt cuts to R\u0026amp;D budgets—pharma R\u0026amp;D fell 2–3% in 2023–24 in some large firms—shifting demand toward more efficient, outsourced and specialized lab space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocal zoning and land-use regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLocal zoning and land-use regulations in core life science markets like Boston, San Francisco Bay, San Diego and Kendall Square directly affect BioMed Realty's pipeline; municipal approvals can change project timelines by 6–24 months and alter buildable density by up to 30% in some jurisdictions.\u003c\/p\u003e\n\u003cp\u003eCity-level political shifts can impose stricter lab safety or setback rules that raise construction costs—recently adding 5–12% per-project—and BioMed actively lobbies and partners with municipalities to align developments with cluster growth and municipal housing\/transport goals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMunicipal approvals: can delay 6–24 months\u003c\/li\u003e\n\u003cli\u003eDensity changes: impact buildable area up to 30%\u003c\/li\u003e\n\u003cli\u003eAdditional lab regulations: increase costs 5–12%\u003c\/li\u003e\n\u003cli\u003eBioMed engagement: formal partnerships and advocacy in key markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTax incentives for life science clusters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState and regional governments offered over $2.1 billion in life-science tax credits and incentives nationwide in 2024, lowering effective entry costs for BioMed Realty tenants and strengthening tenant retention in key clusters like Boston, San Diego, and Research Triangle Park.\u003c\/p\u003e\n\u003cp\u003eThese incentives—including property tax abatements and R\u0026amp;D credits—help maintain higher occupancy and justify premium rents in BioMed’s lab-heavy portfolio, where life-science net operating income outperformed core industrial assets by ~150 basis points in 2024.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, shifts in incentive structures (e.g., reduced capex credits in some states) could redirect BioMed’s capital deployment toward jurisdictions preserving or expanding incentives, affecting site selection and pipeline timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: $2.1B+ national life-science incentives\u003c\/li\u003e\n\u003cli\u003eKey clusters: Boston, San Diego, RTP\u003c\/li\u003e\n\u003cli\u003eBioMed lab NOI ~150 bps higher vs industrial in 2024\u003c\/li\u003e\n\u003cli\u003e2025 incentive cuts may reallocate capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomed funding fuels lab demand, but regs, zoning and pharma margin pressure threaten NOI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical support for biomed funding (NIH $47.5B FY2024; UKRI £3.6B 2024–25) and $2.1B+ state incentives in 2024 underpin BioMed Realty demand, while proposed US FY2026 R\u0026amp;D shifts and IRA-driven pharma margin pressure risk softer leasing; municipal zoning delays (6–24 months) and added lab regs (costs +5–12%) materially affect pipeline timing and NOI.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding\u003c\/td\u003e\n\u003ctd\u003e$47.5B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUKRI\u003c\/td\u003e\n\u003ctd\u003e£3.6B (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState incentives\u003c\/td\u003e\n\u003ctd\u003e$2.1B+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMunicipal delays\u003c\/td\u003e\n\u003ctd\u003e6–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdded lab cost impact\u003c\/td\u003e\n\u003ctd\u003e+5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect BioMed Realty across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—each backed by current data and trends to identify threats and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses BioMed Realty's PESTLE into a succinct, shareable summary that highlights regulatory, economic, and technological risks for quick use in strategy meetings or slide decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment and capital costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a capital-intensive landlord of life-science campuses, BioMed Realty is highly sensitive to cost of debt and equity; US 10-year Treasury yields fell from ~4.5% in mid-2023 to ~3.8% by Dec 2025, easing borrowing costs and lowering cap rates in the sector. Stabilized rates by end-2025 improved feasibility of new lab developments, increasing investment spreads and supporting higher asset valuations—transaction cap rates for life-science assets compressed ~50–100 bps in 2024–25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVenture capital funding for biotechnology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe financial health of BioMed Realty’s tenant base is tied to VC flows: biotech VC funding fell from a peak of about $47B in 2021 to roughly $28B in 2023 but recovered to an estimated $34B in 2024, supporting demand for flexible lab space; sustained VC\/PE inflows drive leasing growth and expansion, while liquidity squeezes during downturns correlate with slower leasing and higher tenant churn—BioMed’s occupancy and leasing velocity track these funding cycles closely.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on construction costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialized lab build-outs cost 30–50% more than standard office fit-outs due to advanced HVAC, cleanroom, and plumbing systems, pushing BioMed Realty’s per-square-foot development costs above the sector average of roughly $400–$800\/sq ft for wet labs versus $200–$400 for offices (2024 estimates).\u003c\/p\u003e\n\u003cp\u003eRising commodity prices—steel up ~12% and copper ~9% in 2024—and a skilled trades wage inflation of 6–8% have compressed development margins and extended delivery timelines for BioMed’s $8–10 billion active pipeline.\u003c\/p\u003e\n\u003cp\u003eThese inflationary pressures directly affect return on invested capital and leasing velocity, making cost-containment, supplier contracting, and schedule risk mitigation critical to preserving profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmployment trends in the life science sector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEmployment growth in pharma and biotech drove US life-science payrolls up 3.8% in 2024, fueling demand for BioMed Realty’s lab and office expansions across key clusters.\u003c\/p\u003e\n\u003cp\u003eHigh researcher employment—Boston, San Francisco Bay and San Diego recorded vacancy rates below 6% in 2024—signals sustained leasing momentum for BioMed assets.\u003c\/p\u003e\n\u003cp\u003eHowever, 2024–2025 industry restructurings raised national life-science sublease inventory to roughly 12–14 million sq ft, pressuring rents in secondary markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 industry payroll +3.8%\u003c\/li\u003e\n\u003cli\u003eCore cluster vacancy \u0026lt;6%\u003c\/li\u003e\n\u003cli\u003eSublease inventory ~12–14M sq ft\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal supply chain resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe life sciences sector depends on timely delivery of lab equipment and consumables; 2024 data shows global supply chain disruptions raised lead times by ~22% and logistics costs by ~18%, risking delayed tenant move-ins for BioMed Realty and higher fit-out expenses.\u003c\/p\u003e\n\u003cp\u003eBioMed must prioritize infrastructure enabling resilient logistics—on-site loading bays, proximity to pharma hubs and cold-chain capacity—to limit vacancy length and protect tenant operating margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: global lead times +22%\u003c\/li\u003e\n\u003cli\u003eLogistics costs +18%\u003c\/li\u003e\n\u003cli\u003eResilient facilities reduce move-in delays and cap fit-out overruns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower USTs and rebounding VC tighten life-science cap rates as lab costs bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLower UST yields (4.5% mid-2023 → ~3.8% Dec 2025) cut cap rates 50–100bps; biotech VC rebounded to ~$34B in 2024 supporting leasing; lab build costs ~$400–$800\/sq ft; 2024 commodity\/wage inflation (steel +12%, copper +9%, trades +6–8%) squeezed margins; life-science payroll +3.8% (2024), core cluster vacancy \u0026lt;6%, sublease ~12–14M sq ft.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUST 10Y\u003c\/td\u003e\n\u003ctd\u003e~3.8% (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC funding\u003c\/td\u003e\n\u003ctd\u003e~$34B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab cost\u003c\/td\u003e\n\u003ctd\u003e$400–$800\/sq ft\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll growth\u003c\/td\u003e\n\u003ctd\u003e+3.8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSublease\u003c\/td\u003e\n\u003ctd\u003e12–14M sq ft\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eBioMed Realty PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact BioMed Realty PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751514091897,"sku":"biomedrealty-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biomedrealty-pestle-analysis.png?v=1772232456","url":"https:\/\/matrixbcg.com\/products\/biomedrealty-pestle-analysis","provider":"matrixbcg.com","version":"1.0","type":"link"}